Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis

Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patient...

Full description

Bibliographic Details
Main Authors: Elinoar Hoffman, Michal A. Rahat, Joy Feld, Muna Elias, Itzhak Rosner, Lisa Kaly, Idit Lavie, Tal Gazitt, Devy Zisman
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:International Journal of Molecular Sciences
Subjects:
rheumatoid arthritis
tocilizumab
lipids
adipokines
adiponectin
resistin
leptin
Online Access:https://www.mdpi.com/1422-0067/20/18/4633

Internet

https://www.mdpi.com/1422-0067/20/18/4633

Similar Items